Navigation Links
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
Date:2/17/2009

in healthy young adults and adults 65 years of age and older are scheduled to begin later this year.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrolment from drug candidates in development by other companies with greater re
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
4. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
5. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
6. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... , the leader in heart rate monitoring and fitness assessment ... Rate Technology Supplier" for U.S. Soccer through 2013.  ... major national and international events, including the London 2012 Olympic ... be used to help these nine National Teams gain a ...
... Feb. 29, 2012  Four Rivers Software Systems, Inc. the ... to the healthcare industry, is pleased to announce ... part of this critical release, we have included ... that will benefit users.  The ...
Cached Medicine Technology:Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 2Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 3Four Rivers Software Systems Launches TMS 2012.5.5 2
(Date:9/19/2014)... who live in leafy, green neighborhoods are less likely to ... suggests. Researchers analyzed data from more than 64,000 births ... in a neighborhood with plenty of trees, grass and other ... birth (before 30 weeks) and a 13 percent lower risk ... born to mothers who lived in greener neighborhoods were also ...
(Date:9/19/2014)... U.S. Food and Drug Administration approved a new type 2 ... class of once-a-week injectable drugs that help manage blood sugar ... is a new treatment option, which can be used alone ... levels in the overall management of type 2 diabetes," Dr. ... Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... Washington, DC (PRWEB) September 19, 2014 ... announced an important partnership with the National Fire ... fire safety. The collaboration, formalized today in a ... empower Alliance Members, factories, workers and other stakeholders ... that will help protect the health and safety ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
(Date:9/19/2014)... September 19, 2014 "I have difficulty ... wrinkles due to stretching the skin around my eyes ... "This inspired me to design a more convenient method ... LENS SYSTEM provides a quicker, easier, more sanitary method ... to perform this task manually, saves time and effort, ...
Breaking Medicine News(10 mins):Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... Company Locations in Alabama, Georgia, Indiana, Iowa, Kansas, ... Texas, Virginia and WisconsinWASHINGTON, Jan. 15 SouthernCare ... the United States a total of $24.7 million ... submitted false claims to the government for patients ...
... coalition of clergy and lay members from faith organizations throughout ... Senator Richard Burr to end his opposition to legislation that ... over tobacco products. The legislation would protect kids from ... to filibuster the legislation if it was brought to the ...
... required for foods from these animals, agency says , , ... and Drug Administration on Thursday issued its final regulations ... rules do not require consumer labeling for foods from ... (rDNA) to introduce new characteristics or traits into an ...
... 15 Boston Scientific Corporation (NYSE: BSX ) today ... Circuit. The case involves a Boston Scientific patent, which in ... the decision, the Court found that the patent was invalid as ... by Johnson and Johnson of a 2005 jury verdict in the ...
... of Trade Alerts on stocks making news today. Investors can ... visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: Eli Lily ... (NYSE: PCS ), ConAgra Foods Inc. (NYSE: ... ), Target Corp. (NYSE: TGT ) and Dow ...
... around 50 percent, despite proven benefits, report says , , THURSDAY, ... colon cancer saves lives, but too few Americans are getting ... report shows. , The rate of screening for breast and ... the rate of colorectal cancer screening has increased but not ...
Cached Medicine News:Health News:Alabama-Based Hospice Company Pays U.S. $24.7 Million to Settle Health Care Fraud Claims 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 3Health News:FDA Issues Final Regulations for Genetically Engineered Animals 2Health News:FDA Issues Final Regulations for Genetically Engineered Animals 3Health News:Boston Scientific Announces Court Decision 2Health News:Boston Scientific Announces Court Decision 3Health News:Beacon Equity Issues Technical Trade Alerts on Headline Stocks: LLY, PCS, CAG, FRX, TGT, DOW 2Health News:More Americans Urged to Get Cancer Screenings 2Health News:More Americans Urged to Get Cancer Screenings 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: